Autopsy report · NCT03159988

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

“Study Suspended. Slow enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Suspended: paused, and may or may not restart.
• 6 participants enrolled.

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

University of Arizona

Sponsor type

University, hospital or other

Conditions

Chronic Heart Failure; Cognitive Impairment

Interventions

Angiotensin-(1-7); Memory Training

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
  “Slow enrollment; study terminated.” (86% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (85% match in meaning)
• Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
  “The study was halted because enrollment was too slow” (82% match in meaning)
• LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
  “Study was discontinued due to slow enrollment” (82% match in meaning)
• Memantine and Antipsychotics Use
  “Study terminated due to too slow enrollment” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.